Olumacostat glasaretil shows benefit in patients with facial acne vulgaris
Olumacostat glasaretil (OG) appears to be effective and is well tolerated in patients with moderate to severe facial acne vulgaris, suggesting the need for further development, according to a new study.
“OG inhibits acetyl-coenzyme A carboxylase, the enzyme responsible for the first, rate-limiting step in de novo fatty acid synthesis,” said researchers. “OG inhibited in vitro human sebocyte lipid production and reduced in vivo sebaceous gland size in hamster ears.”
To assess the safety and efficacy of OG 7.5 percent gel in patients (n=108) with moderate to severe facial acne vulgaris, researchers conducted a randomized trial. Patients were randomly assigned to either twice-daily application of OG (n=53) or vehicle (n=55) for 12 weeks.
They measured OG’s efficacy through changes in lesion counts and improvement in acne severity scores.
The OG and vehicle groups had mean baseline counts of 29.7 and 28.6 inflammatory, and 40.9 and 38.8 noninflammatory lesions, respectively.
Compared with vehicle, OG treatment at week 12 showed higher reductions from baseline in inflammatory lesions (–45.9 vs –63.9 percent; p=0.0006) and noninflammatory lesions (–28.8 vs –48.1 percent; p=0.0025), and more patients with ≥2-grade improvement in investigator global assessment score (7.3 vs 24.5 percent; p=0.007).
However, more application-site adverse events (typically mild or moderate intensity) occurred in the OG group, according to researchers, adding that larger trials are required to optimize OG dosing and confirm the current findings.